Figure 3 | Scientific Reports

Figure 3

From: E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments

Figure 3

The E2F transcriptional signature doesn’t predict the PDAC sensitivity to cytotoxic drugs in vitro. (a) Chemograms assays showing the sensitivity of the E2F high cell lines (in red) and E2F low cell lines (in blue) to five chemotherapeutics drugs commonly using in clinic (gemcitabine, 5-FU, oxaliplatin, docetaxel and irinotecan). The concentrations of each drug vary from 1 nM to 1 M (b) Box plots representing the IC50 values were calculated using nonlinear regression of the log([drug]) versus normalized curve with robust fit shown in a.

Back to article page